Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene

Abstract

The article presents the results of pharmacoeconomic study concerning different approaches to treat patients with non-small cell lung cancer and mutations in the EGFR gene. We have compared two common therapy regimens, which are used in routine practice in this group of patients, nowadays: the standard chemotherapy - carboplatin/paclitaxel combination and targeted therapy, using gefitinib. The results of the study demonstrate the clinical and economic benefits of gefitinib, proved by preferable cost-effectiveness ratio and reduced financial costs taking into account the effective treatment ratio patients/months.

Keywords

• pharmacoeconomic analysis
• cost-effectiveness
• effective treatment ratio patients/months
• non-small cell lung cancer
• mutation in the egfr gene
• gefitinib
• carboplatin/paclitaxel